Abstract
BackgroundThe NOR-SWITCH study was a 52-week randomized, double-blind, non-inferiority, phase IV switch trial in patients with Crohn's disease (CD), ulcerative colitis (UC), spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have